Dear Friends of the Termeer Institute, The Termeer Institute is leading the way into a new era in life sciences—one where values-driven leaders are supported, empowered,and connected; scientific discovery knows no borders; and the exchange of ideas and experiences...

Leadership in biotech is often characterized by milestones, strategy, and scientific rigor. Yet for many leaders navigating a demanding, high-stakes industry, the most defining experience isn’t the technical work—it’s the isolation that comes with carrying...

Boston, MA (September 8, 2025)— The Termeer Institute today announced that Catharine Smith has been named Chief Executive Officer, reflecting her established leadership of the organization and the importance of the role to guide the Institute’s mission to become a...

Introducing the Termeer Institute: A New Chapter in Patient-Centered Life Science Leadership  The Termeer Institute, formerly the Termeer Foundation, focuses on developing life science entrepreneurs, building community, and convening stakeholders to advance cures for...

This year’s recipients reflect a deep commitment to advancing therapies that help patients — and the world The Termeer Foundation announced today this year’s Transatlantic Connections Award honorees, an award that honors two life sciences entrepreneurs — one in the...

Termeer Foundation announces its Class of 2025 Termeer Fellows Incoming class reflects an increasing global footprint and engagement in multiple biotech ecosystems Today the Termeer Foundation announced its largest class of Termeer Fellows to date, with 17 first-time...

Join Hans Schikan, Co-Founder and Vice Chairman of Pharvaris and Termeer Foundation mentor, as he hosts an engaging conversation about patient-centered innovation. Hans welcomes Koenraad Wiedhaup, CEO of Leyden Labs, a company dedicated to eradicating viral threats,...

Having a child with a rare or ultra-rare disease often means traveling a lonely, uncertain path. Doctors may be unfamiliar with the condition and unsure how to diagnose or treat it — presuming treatments exist, which typically they do not. And it is unlikely that...

Looking across the biopharmaceutical industry landscape, several noteworthy medical advances have occurred in the last year. According to a recent article in STAT, new drugs for schizophrenia, muscular dystrophy, and pulmonary hypertension are among the most...

As we close out 2024—a year marked by political, social, and industry challenges—this conversation explores how biotech leaders can prioritize renewal and resilience. Join Michèle Berg, Managing Director of Envisage Consulting and executive coach, content consultant...